DEG6498 / Degron Therap - LARVOL DELTA

Molecular glue degraders of the RNA binding protein HuR to treat BRAF-mutant colorectal cancer (AACR 2026) - "A Phase I clinical trial has been initiated to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of DEG6498 in patients with advanced solid tumors, including BRAF-mutant CRC as an expansion cohort. This trial marks a significant milestone as the first-in-human study of a HuR-targeted molecular glue degrader, offering a novel therapeutic strategy with a distinct mechanism of action to overcome the limitations of current targeted therapies for this aggressive cancer subset."

First-in-human • Colorectal Cancer • Oncology • Solid Tumor • BRAF • CRBN • IL17RB

A First in Human Phase 1 Open-Label, Multicenter, Dose Escalation and Expansion Study of DEG6498 in Patients With Solid Tumors (ChiCTR) - P1 | N=80 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Degron Therapeutics

New P1 trial • Hepatocellular Cancer • Solid Tumor • BRAF

A Study of DEG6498 in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Degron Therapeutics Co. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor • BRAF

A Study of DEG6498 in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Degron Therapeutics Co.

First-in-human • New P1 trial • Oncology • Solid Tumor • BRAF